Reprint
Novel Biomarkers for Heart Disease
Edited by
December 2020
420 pages
- ISBN978-3-03943-883-9 (Hardback)
- ISBN978-3-03943-884-6 (PDF)
This book is a reprint of the Special Issue Novel Biomarkers for Heart Disease that was published in
Medicine & Pharmacology
Public Health & Healthcare
Summary
Cardiac biomarkers such as troponins and natiuretic peptides have made a great impact on clinical decision making as well as improving our understanding of molecular mechanisms of different disease conditions. However, the biomarkers that are currently in use do not reflect all the multiple disease pathways that are involved in a broad spectrum of cardiac disease conditions ranging from acute coronary syndrome, to heart failure (and heart failure with preserved ejection fraction, HFpEF), to pulmonary hypertension or arrhythmias. In this Special Issue, we will provide an overview of the current developments in the field of biomarker research, beginning with research on molecular pathways and cellular communication (e.g., microRNA) up to the clinical use of biomarkers.
Format
- Hardback
License
© 2021 by the authors; CC BY-NC-ND license
Keywords
diet quality; ceramides; obesity; cardiovascular risk; healthy eating index; carbohydrate antigen-125; heart failure; inflammatory marker; older women; biomarker; cardiometabolic disease; epicardial adipose tissue; epicardial fat; epicardial fat volume; microRNA; thyroid-stimulating hormone; cardiometabolic risks; metabolic syndrome; obesity; hypertension; very low-density lipoprotein; metabolic syndrome; STIM1; SOCE; atrial myopathy; atrial fibrillation; heart failure; ejection fraction; soluble urokinase-type plasminogen activator receptor (suPAR); growth differentiation factor 15 (GDF-15); heart-type fatty acid-binding protein (H-FABP); soluble suppression of tumorigenicity 2 (sST2); acute myocardial infarction; biomarkers; catestatin; coronary artery disease; heart failure; heart failure decompensation; left ventricular ejection fraction; troponin; NT-proBNP; NYHA functional class; GDF-15; cardiovascular surgery; operative risk; biomarkers; muscle wasting; sarcopenia; renal dysfunction; chronic kidney disease; aortic disease; aneurysm; miRNA; TGF-β pathway; KLF4; synthetic phenotype; aortic regurgitation; echocardiography; magnetic resonance imaging; vena contracta area; longitudinal strain; T1 mapping; GDF8; myostatin; AMI; troponin; ceruloplasmin; NT-proBNP; heart failure; H-FABP; heart-type fatty acid-binding protein; FABP3; fatty acid-binding protein 3; heart failure; HF; cardiac biomarkers; cardiac magnetic resonance imaging; heart failure; left ventricular systolic function; magnetic resonance spectroscopy; myocardial triglyceride content; biomarkers; cell adhesion molecule; heart failure; repeated measurements; pregnancy-associated plasma protein-A; coronary artery disease; cohort studies; biomarkers; cardiovascular diseases; mitochondrial dysfunction; circulating cells; PBMCS; platelets; oxidative stress; reactive oxygen species (ROS); mitochondrial DNA (mtDNA); biomarkers; herat failure; liver-type fatty-acid-binding protein; long-term outcomes; cardiac intensive care units; acute kidney injury; myocardial infarction; STEMI; cardiovascular events; cardiovascular death; risk stratification; sST2; NT-proBNP; Pentraxin-3; sudden cardiac death; ventricular arrhythmia; ventricular tachycardia; biomarkers; cardiac biomarkers; heart failure; chronic heart failure; saliva; oxidative stress; salivary biomarkers; CKD; CVD; biomarkers; sST2; STEMI; PPCI; left ventricular adverse remodelling; circulating miRNAs; NAFLD; cardiovascular risk; Framingham risk score; CVD; risk prediction; secondary prevention; primary prevention; metabolic syndrome; NAFLD fibrosis score; HFpEF; heart failure; HFrEF; biomarker; sST2; suPAR; H-FABP; sST2; n/a